(Q40757945)

English

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

scientific article published on 12 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Juliana Chung-ngor Chan

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

author name string

Changyu Pan

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Ping Han

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Qiuhe Ji

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Chengjiang Li

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Juming Lu

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jinkui Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Wenhui Li

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Jiaoe Zeng

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

An-Tsz Hsieh

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

12 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Journal of diabetes

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

386-395

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Prevalence and control of diabetes in Chinese adults

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Standards of medical care in diabetes--2013

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

GIP and GLP-1, the two incretin hormones: Similarities and differences

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Epidemic obesity and type 2 diabetes in Asia

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Larger Amounts of Visceral Adipose Tissue in Asian Americans

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12425

21 January 2018

Identifiers

10.1111/1753-0407.12425

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40757945&oldid=1906726842"